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Abstract
Background: Mycobacterium tuberculosis topoisomerase I (MtTOP1) and Escherichia coli topoisomerase I have
highly homologous transesterification domains, but the two enzymes have distinctly different C-terminal domains.
To investigate the structure-function of MtTOP1 and to target its activity for development of new TB therapy, it is
desirable to have a rapid genetic assay for its catalytic activity, and potential bactericidal consequence from
accumulation of its covalent complex.
Results: We show that plasmid-encoded recombinant MtTOP1 can complement the temperature sensitive topA
function of E. coli strain AS17. Moreover, expression of MtTOP1-G116 S enzyme with the TOPRIM mutation that
inhibits DNA religation results in SOS induction and loss of viability in E. coli. The absence of cysteine residues in
the MtTOP1 enzyme makes it an attractive system for introduction of potentially informative chemical or
spectroscopic probes at specific positions via cysteine mutagenesis. Such probes could be useful for development
of high throughput screening (HTS) assays. We employed the AS17 complementation system to screen for sites in
MtTOP1 that can tolerate cysteine substitution without loss of complementation function. These cysteine
substitution mutants were confirmed to have retained the relaxation activity. One such mutant of MtTOP1 was
utilized for fluorescence probe incorporation and fluorescence resonance energy transfer measurement with
fluorophore-labeled oligonucleotide substrate.
Conclusions: The DNA relaxation and cleavage complex accumulation of M. tuberculosis topoisomerase I can be
measured with genetic assays in E. coli, facilitating rapid analysis of its activities, and discovery of new TB therapy
targeting this essential enzyme.
Background
DNA topoisomerases maintain the proper topological
state of DNA required for vital cellular functions to pro-
ceed. The change in DNA topology is catalyzed via con-
certed breaking and rejoining of DNA coupled with DNA
strand passage [1], forming a covalent topoisomerase com-
plex with cleaved DNA as the catalytic intermediate. The
accumulation of the covalent complex accounts for the
lethal effects of many topoisomerase inhibitors that are
utilized as anticancer or antibacterial drugs in therapeutic
applications [2-5]. These drugs target type IB and type IIA
topoisomerases, classified according to their structural and
mechanistic properties. Discovery of similar topoisomerase
poison inhibitors for type IA topoisomerases, which
include bacterial topoisomerase I enzyme, could lead to
the discovery of novel antibacterial agents that can be
used for treatment of multi-drug resistant bacterial patho-
gens. It has been demonstrated via mutants defective in
DNA rejoining that accumulation of E. coli or Yersinia
pestis topoisomerase I cleavage complex in E. coli leads to
* Correspondence: yuk-ching_tse-dinh@nymc.edu
Department of Biochemistry and Molecular Biology, New York Medical
College, Valhalla, New York 10595, USA
Narula et al. BMC Biochemistry 2010, 11:41
http://www.biomedcentral.com/1471-2091/11/41
© 2010 Narula et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.rapid bacterial cell death [6,7] validating bacterial topoi-
somerase I as a new therapeutic target [8]. In addition to
poison inhibitors, catalytic inhibitors that act by a different
mechanism could also be useful therapeutic agents for
bacterial pathogens that require a functional topoisome-
rase I enzyme for viability or pathogenicity. It has been
suggested that at least one type IA topoisomerase enzyme
activity must be present in each organism for resolving
topological barriers that require single-stranded DNA
cleavage [9]. Unlike E. coli, which encodes topoisomerase
III as a second type IA topoisomerase, M. tuberculosis
has only one type IA topoisomerase activity. Results
from previous transposon mutagenesis studies strongly
suggest that the topoisomerase I function is required for
M. tuberculosis growth and survival during infection
[10,11]. M. tuberculosis topoisomerase I (MtTOP1) has
been proposed as a target for discovery of new TB drugs
[12] that are urgently needed due to the large number of
human deaths caused by TB globally, and the increasing
incidence of TB strains resistant to all available current
drugs.
To study the structure-function of MtTOP1 and to
monitor its activity, it would be desirable to have a
rapid genetic assay for its specific function. The E. coli
strain AS17 [13] has a mutation in the chromosomal
topA gene that reduces the topoisomerase I relaxation
a c t i v i t y ,w i t hg r o w t hp e r m i s s i b l ea t3 0 ° Cb u tn o n -
permissive at 42°C unless complemented by recombi-
nant relaxation activity [14,15]. The topoisomerase I
enzyme of E. coli and M. tuberculosis shares a highly
homologous transesterification domain (~67,000 kDa)
that is conserved among all type IA topoisomerases.
It contains the active site tyrosine residue for nucleophi-
lic attack of DNA in the formation of the covalent clea-
vage complex, and residues in the TOPRIM domain
required for coordination of Mg
2+ during catalysis [16].
DNA cleavage site selectivity was found to involve the
preference of a cytosine at the-4 position relative to the
cleavage sites preferred by topoisomerase I and reverse
gyrase enzymes in the type IA family of topoisomerases
[17-19]. However, the transesterification domain cannot
carry out relaxation of negative supercoils in the absence
of the C-terminal domain [14]. The C-terminal domains
of E. coli and M. tuberculosis topoisomerase I belong to
two distinct families. The C-terminal domain of E. coli
topoisomerase I has multiple tetracysteine motifs for
coordination of Zn(II) ions required for relaxation activ-
ity [20], while the C-terminal domains of topoisomerase
If o u n di nMycobacterium smegmatis and M. tuberculo-
sis were found not to have any Zn(II) coordinating tetra-
cysteine motifs [21].
In addition to the difference between the C-terminal
domain sequences of Mycobacterium and E. coli topoi-
somerase I, it is also unclear if MtTOP1 can be functional
in E. coli due to the significant difference in codon
usage between E. coli and M. tuberculosis.T h es t r u c -
ture-function study of MtTOP1 would be greatly facili-
tated if a rapid genetic assay system utilizing E. coli
can be established. For further study of the enzymatic
properties of MtTOP1, we have initiated biochemical
studies of MtTOP1 to take advantage of the absence
of cysteine residue in its sequence. If a unique cysteine
can be introduced into a specific position via site-
directed mutagenesis without diminishing the catalytic
activity, spectroscopic or chemical probes can then be
introduced to study the protein-DNA interactions
involved in catalysis. Spectrophotometric analysis utiliz-
ing these probes could potentially be developed into
HTS assay for identification and characterization of
small molecule inhibitors of MtTOP1.
In this study, we demonstrated that plasmid encoding
MtTOP1 can complement E. coli AS17 with temperature
sensitive topA [13] for growth at 42°C. In addition to
demonstrating that the relaxation activity of wild-type
MtTOP1 was functional in E. coli,w ea l s os h o w e dt h a t
when a mutant version of MtTOP1, with the G116
S TOPRIM mutation that inhibits DNA religation [6]
was overexpressed in E. coli, the SOS response is induced
along with a significant decrease in viability. Therefore,
the accumulation of cleavage complex formed by
MtTOP1 can also be assayed in E. coli. We utilized the
E. coli genetic system to identify a number of positions in
MtTOP1 that could be mutated to cysteine with little or
no loss of relaxation activity. The retention of relaxation
activity was confirmed after the expression and purifica-
tion of the mutant enzymes. One such cysteine substitu-
tion mutant enzyme MtTOP1-K524C was conjugated to
a fluorescence dye for fluorescence resonance energy
transfer (FRET) study with fluorescence-labeled oligonu-
cleotide substrates.
Results
Complementation of topA function in E. coli AS17 for
growth at 42°C by M. tuberculosis topoisomerase I
E. coli AS17 transformed with plasmid pMTOP was
streaked onto LB plates with ampicillin and incubated at
either 30°C or 42°C. Plasmid pETOP expressing recombi-
nant E. coli topoisomerase I in the same vector was used
as positive control. Complementation for growth at 42°C
c o u l db eo b s e r v e dw i t hb o t hp M T O Pa n dp E T O P .N o
complementation for growth at 42°C could be seen with
the vector pBAD/thio (Figure 1). This result showed that
the recombinant MtTOP1 interacts with the chromoso-
mal DNA in E. coli, and the background uninduced
expression of MtTOP1 from the BAD promoter in
pMTOP clone was sufficient for complementation of the
temperature sensitive topA function in E. coli AS17 for
growth at 42°C. Even though E. coli and M. tuberculosis
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domain sequences, the conservation of the N-terminal
transesterification domaini nM t T O P 1i sl i k e l yt oa l l o w
MtTOP1 to bind to single-stranded DNA associated with
negatively supercoiled region of the E. coli chromosome
to remove excess negative supercoils.
Cell killing from accumulation of mutant MtTOP1
covalent complex in E. coli
The TOPRIM motif DxDxxG is strictly conserved in type
IA topoisomerase sequences and plays an essential role
for divalent ion coordination and cleavage-religation of
DNA during catalysis [16,22,23]. For recombinant E. coli
or Y. pestis topoisomerase I, mutation of the first aspar-
tate residue in the TOPRIM motif to asparagine has been
shown to be extremely lethal to E. coli [7]. Substitution
of the conserved glycine in the TOPRIM motif with
serine in E. coli or Y. pestis topoisomerase I resulted in
mutant topoisomerase I enzyme capable of DNA clea-
vage but defective in DNA religation [6]. Induction of the
BAD promoter regulating the expression of these Gly to
Ser mutant E. coli and Y. pestis topoisomerases resulted
in loss of viability of the host E. coli cells [6].
An attempt was made to introduce the Asn substitu-
tion at the first Asp of the TOPRIM motif found in
MtTOP1 (Asp111) by site-directed mutagenesis. Clones
of pMTOP with the desired D111N mutation as a single
substitution could not be isolated after transformation
of commonly used E. coli cloning strains even in the
presence of 2% glucose to suppress transcription from
the BAD promoter regardless of the recA genotype of
the E. coli host cells. This was likely due to the toxic
effect of the mutant MtTOP1 background expression
on E. coli viability. All the isolated clones had second
site mutations, similar to what was observed during
attempted construction of E. coli and Y. pestis topoi-
somerase I mutants with the D111N mutation [7]. This
suggested that E. coli host cells can be very vulnerable
to accumulation of covalent cleavage complex formed
by recombinant MtTOP1 enzyme in vivo.
The G116 S mutation in E. coli topoisomerase I has a
lesser lethal effect when compared to the D111N muta-
tion because it accumulates lower amounts of cleavage
complex [7]. The Ser substitution was successfully made
at Gly116 of the MtTOP1 TOPRIM motif in pMTOP
and a clone with no second-site mutation was isolated in
t h ep r e s e n c eo f2 %g l u c o s e . The mutant MtTOP1-G116
S enzyme was expressed by arabinose induction and puri-
fied. Mg
2+ ions are required for DNA religation and
relaxation activity of all type IA topoisomerases [24,25].
Mg
2+ ions did not have to be added for DNA cleavage to
be observed by wild-type MtTOP1 (Figure 2A), but the
DNA cleavage activity of MtTOP1-G116 S is Mg
2+
dependent, similar to the Gly to Ser substitution mutants
previously characterized for E. coli and Y. pestis topoi-
somerase I [6]. Quantitation of the nicked DNA formed
(additional file 1: Quantitation of DNA nicking by
M t T O P 1 - G 1 1 6 S )s h o w e dt h a t~ 3 0 %o ft h ei n p u tD N A
could be converted to the nicked form by MtTOP1-G116
S in the presence of MgCl2. No relaxation activity could
30oC               42oC
M M
E VE V
Figure 1 Complementation of topA
ts function in E. coli AS17 by recombinant M. tuberculosis topoisomerase I. Transformants of E. coli
AS17 with pMTOP (M), pETOP (E) and vector pBAD/thio (V) were streaked on LB plates with 100 μg/ml ampicillin and incubated at the indicated
temperature for 48 h.
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loss of DNA religation activity even in the presence of
high concentrations of Mg
2+ ions (Figure 2B).
Plasmid pMTOP-G116S was transformed into E. coli
strain JD5 and the transformants were first isolated in
the presence of 2% glucose. The transformants were then
replica plated onto Xgal indicator plate with 0.002% ara-
binose to increase the level of synthesis of mutant
MtTOP1-G116 S. SOS response to the accumulated clea-
vage complex was evident from the blue color of the
colonies in the presence of 0.002% arabinose resulting
from induction of the lacZ gene under the control of the
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Figure 2 Analysis of biochemical properties of MtTOP1-G116 S enzyme and the lethal consequence of its overexpression. (A) Magnesium
dependence of DNA cleavage. Wild-type and G116 S MtTOP1 proteins were assayed for cleavage of negatively supercoiled plasmid DNA with
agarose gel electrophoresis in the presence of 0.5 μg/ml ethidium bromide. N: nicked DNA; S: supercoiled DNA (B) MtTOP1-G116 S mutant has no
relaxation activity even in the presence of excess Mg(II) ions. Wild-type and G116 S mutant MtTOP1 (400 ng) were assayed in a 20 μl reaction with
10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 0.1 mg/ml gelatin and the indicated concentration of MgCl2 at 37°C for 30 min. Agarose gel electrophoresis in
the absence of ethidium bromide was used to separate the supercoiled DNA from the slower migrating relaxed topoisomers. (C) Loss of viability of
E. coli JD5 after induction of MtTOP1-G116 S expression with arabinose. Viable colony counts determined 2 h after addition of 0.2% arabinose were
divided by viable colony counts from control non-induced cultures to obtain the survival ratio.
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nential phase culture of JD5/pMTOP-G116 S with 0.2%
arabinose for 2 h resulted in a viable colony count ratio
of ~10
-4 when the number of viable colonies from
induced culture were divided by the viable colony counts
from the non-induced culture (Figure 2C). Induction of
w i l d - t y p eM t T O P 1b y0 . 2 %a r a b i n o s er e d u c e dt h ev i a b l e
counts of E. coli J D 5b yo n l y~ 2f o l d .T h ed e g r e eo fl o s s
of viability from the Gly to Ser mutation in pMTOP was
similar to that observed previously for the same mutation
in pETOP [6]. These results showed that the accumula-
tion of the covalent cleavage complex formed by recom-
binant MtTOP1 in E. coli could result in SOS induction
and bacterial cell death.
Assay of relaxation activity of cysteine-substitution
mutants of MtTOP1 by complementation of E. coli
topA function
MtTOP1 protein from M. tuberculosis H37Rv has the
very useful property of having no cysteine residues in its
sequence. It is thus an ideal model system for biochem-
ical studies where a unique cysteine can be introduced by
site-directed mutagenesis to facilitate chemical conjuga-
tion of fluorescence or affinity probe at a specific posi-
tion. Expression and purification procedures utilizing
plasmid pLIC-MTOP have been developed to produce
milligram quantities of soluble and active MtTOP1 pro-
tein [17]. Even though the pLIC-MTOP plasmid requires
induction of the T7 promoter for high level protein
expression, there is likely to be a certain level of constitu-
tive background expression in the absence of T7 RNA
polymerase induction, similar to background expression
of MtTOP1 from pMTOP in the absence of arabinose
induction of the BAD promoter. This background expres-
sion in pLIC-MTOP was found to be sufficient for com-
plementation of the topA function of E. coli AS17 for
growth when plates incubated at 30°C and 42°C were
compared (Figure 3). Transformation of E. coli AS17 with
the corresponding vector or plasmid expressing the active
site mutant MtTOP1-Y342A did not result in comple-
mentation. A number of residues in MtTOP1 were
selected for cysteine substitution based on the criteria
that the residues are not highly conserved in identity, but
are positioned near strictly conserved residues [26].
These are shown on the model structure of MtTOP1 in
MODBASE [27] derived from the crystal structure of the
N-terminal domain of E. coli topoisomerase I 1MW9
(Figure 4). pLIC-MTOP derivatives with these single
cysteine substitution were transformed into E. coli AS17.
Complementation of the temperature sensitive topA func-
tion in E. coli AS17 was assayed by growth of the trans-
formants at 42°C, as shown for MtTOP1-K524C mutant
(Figure 3), or more quantitatively by plating serial
dilutions of the AS17 transformant culture and compar-
ing the number of viable colonies obtained after incuba-
tion at either 30°C or 42°C (Table 1). There was no
complementation from the Y342A or G116 S MtTOP1
mutants as expected. The results from the cysteine sub-
stitutions mutants suggested that cysteine substitution at
most of the positions tested could be tolerated without
significantly affecting the ability of MtTOP1 to comple-
ment the topA chromosomal mutation in AS17 for
growth at the non-permissive temperature.
To confirm the retention of relaxation activity after the
cysteine substitution, mutant MtTOP1 enzymes with
cysteine substitutions at H139, Y174, and K524 residues
located in different regions of the enzyme were expressed
and purified for further characterization. In vitro assay of
the relaxation activity (Figure 5) confirmed that these
enzymes with a single cysteine introduced by mutagen-
esis had close to wild-type relaxation activity.
CPM-MtTOP1-K524C relaxation activity and FRET
experiments
MtTOP1-K524C was labeled with CPM as described in
Materials and Methods. After labeling, the activity of
the labeled enzyme was checked by relaxation activity
assay. As shown in Figure 6, labeling with CPM did not
affect the activity of the K524C mutant enzyme. The
labeled MtTOP1-K524C demonstrated relaxation activ-
ity comparable to unlabeled MtTOP1-K524C. For the
FRET experiments, a 35-base oligonucleotide substrate
was designed to have a stem-loop structure providing
the enzyme with both a single-stranded and a double-
stranded region for potential interaction. This oligo was
labeled with fluorescein at 3 positions: 3’ end, 5’ end
and an internal location within the single-stranded loop.
Upon titration of CPM-MtTOP1-K524C with substrate
labeled with fluorescein at either the 5’ or 3’ end, no
FRET was observed (Figure 7B, C). However, upon titra-
tion with substrate labeled with fluorescein in the sin-
gle-stranded loop, a large drop in the CPM emission
(470 nm) and a corresponding increase in the fluores-
cein emission (520 nm) indicated the occurrence of
FRET (Figure 7A). The resul t so b t a i n e df r o mt h eF R E T
experiments were used to calculate the energy transfer
efficiency (E). The maximum transfer efficiency was
observed upon titration with the internally labeled oligo
(0.72). Titration with the 3’ and the 5’ labeled oligo
demonstrated transfer efficiencies of 0.45 and 0.39
respectively.
We found that MtTOP1-H139C protein could also be
labeled with fluorophores with no significant loss of
relaxation activity (results not shown). However, FRET
was not observed in similar studies of labeled MtTOP1-
H139C with oligonucleotide substrates.
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Figure 3 Complementation assay of E. coli AS17 by pLIC-MTOP. encoding wild-type MtTOP1 (W), and mutants MtTOP1-Y342A (Y) and
MtTOP1-K524C (K). V: LIC vector.
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Figure 4 Sites of cysteine substitutions shown on structural model of MtTOP1 N-terminal transesterification domain. The active site
tyrosine Y342 is also shown for reference.
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Due to the requirement of topoisomerase I function for
M. tuberculosis growth and survival during infection as
indicated by transposon mutagenesis studies [10,11], dis-
covery of specific inhibitors of MtTOP1 could lead to
development of novel therapeutics urgently needed for
treatment of multi-drug resistant TB. The utilization of
MtTOP1 as a potential new drug target would be facili-
tated by development of simple assays for the catalytic
function of the enzyme. It is also desirable to identify
poison inhibitors that can result in accumulation of the
covalent complex of MtTOP1, since such topoisomerase
poison inhibitors are expected to be bactericidal, and
might be useful when used in combination therapy with
current TB drugs such as fluoroquinolones [28].
The results described here demonstrated that inhibi-
tion of DNA religation by recombinant MtTOP1 would
result in killing of the E. coli host cells. Increased
expression of recombinant MtTOP1 should result in
hypersensitivity to its poison inhibitors. The catalytic
function of recombinant MtTOP1 could also be assessed
easily from its complementation of the temperature
sensitive topA function in E. coli AS17 at the non-
permissive temperature. Despite a potential problem
from difference in codon preference of the different
organisms, and divergence of the topoisomerase I
C-terminal domain sequences, recombinant MtTOP1
could still form covalent cleavage complex on the E. coli
chromosome and remove excess negative supercoils so
that viable functions can proceed.
The E. coli cell based assays are useful in structure-
function studies of the enzyme. Mutations that abolish
the catalytic activity after amino acid substitutions, such
as Y342A and G116 S, could be identified readily. In
another approach to study the enzyme mechanism,
cysteine mutagenesis sites in different regions of the
enzyme which do not affect the enzyme activity could
also be determined rapidly by using the E. coli AS17
complementation assay. These cysteine substitutions are
designed to take advantage of the absence of cysteine in
wild-type MtTOP1 sequence to introduce a sulfhydryl
Table 1 Effect of MtTOP1 substitutions on the
complementation of topA
ts function in E. coli AS17 at the
non-permissive temperature
Plasmid Complementation ratio
pLIC vector 3.9 × 10
-5 ± 3.3 × 10
-5
pLIC-ETOP 0.58 ± 0.21
pLIC-MTOP 0.53 ± 0.24
pLIC-MTOP-Y342A 1.1 × 10
-4 ± 1.1 × 10
-4
pLIC-MTOP-G116S 3.3 × 10
-5 ± 2.0 × 10
-5
pLIC-MTOP-M136C 2.7 × 10
-4 ± 4.1 × 10
-4
pLIC-MTOP-H139C 0.19 ± 0.15
pLIC-MTOP-T142C 0.097 ± 0.029
pLIC-MTOP-L170C 0.32 ± 0.16
pLIC-MTOP-Y174C 0.18 ± 0.06
pLIC-MTOP-K524C 0.33 ± 0.17
Serial dilutions of overnight cultures of E. coli AS17 transformants were plated
on LB plates with kanamycin and incubated for 2 days at either 30°C or 42°C.
Colony counts from 42°C incubation were divided by colony counts from 30°C
to obtain the complementation ratios. The results represent the average and
standard deviation from at least three measurements.
0   200  20   2   200  20   2  200  20   2   200  20   2  ng enzyme
WT K524C Y174C H139C
Figure 5 Relaxation activity assay of H139C, Y174C and K524C mutants of MtTOP1. Serial dilutions of purif i e dw i l d - t y p eM t T O P 1a n d
mutant derivatives with cysteine substitutions at H139, Y174 and K524 were added to 20 μL reaction volume of 10 mM Tris-HCl, pH 8.0, 50 mM
NaCl, 0.1 mg/mL gelatin, 6 mM MgCl2 and 0.2 μg of supercoiled plasmid DNA. Incubation was at 37°C for 30 min.
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probe at a unique position on the enzyme. Cysteine
mutants that could complement AS17 for growth at
non-permissive temperature were found to have close to
wild-type relaxation activity when purified, confirming
the effectiveness of the genetic assay.
For CPM fluorophore introduced at residue K524,
FRET was observed with fluorescein fluorophore placed
in the single stranded region of the substrate, but not at
the double stranded region. In the mechanistic model
proposed for the relaxation of DNA by topoisomerase I
[25], a single strand of DNA passes into the interior cav-
ity of the enzyme in order to change the linking number
of the DNA substrate. That would place the loop region
of the single-stranded DNA in the vicinity of K524,
accounting for FRET between CPM-MtTOP1-K524C
and fluorescein in the single-stranded loop region of the
substrate. The double-stranded region of the DNA sub-
strate may extend from the DNA binding groove formed
by subdomains I and IV [29], further away from the
interior cavity of the enzyme and K524, explaining the
absence of FRET when fluorescein was placed at the 5’
or 3’ end of the DNA substrate. Although H139 is closer
t ot h ea c t i v es i t et y r o s i n eY 3 4 2t h a nK 5 2 4 ,b i n d i n go f
the stem region of the DNA substrate in subdomain IV
would place the DNA in opposite direction from the
active site away from H139, too far for FRET to take
place. We tried to attach fluorescent probes with the
Y174C mutant, but the labeling efficiency was poor.
Other cysteine substitution mutants will be explored in
future related mechanistic studies. Cysteine substitution
mutants of MtTOP1 could potentially be utilized for
development of enzyme based HTS assays for inhibitors
of MtTOP1 activity.
The E. coli cell based assays could also be useful for
testing potential MtTOP1 inhibitors. Whole cell screen-
ings has identified a large number of small molecules
that can inhibit the growth of M. tuberculosis [30,31],
but it is often difficult to quickly determine the cellular
target of antibacterial compounds without extensive
follow up investigations. Previous studies showed that
the topA function in E. coli AS17 can also be comple-
mented by the type IB topoisomerase gene from Sac-
charomyces cerevisae [32]. Since the type IA and type IB
topoisomerases have distinctly different structures and
mechanisms, an inhibitor with high specificity against
type IA topoisomerase would affect growth of E. coli
AS17 complemented by MtTOP1 activity at the non-
permissive temperature, but should have much lower
antibacterial activity against E. coli AS17 complemented
by yeast topoisomerase I. This complementation assay
system should facilitate the identification of lead com-
pounds that have antibacterial activity due to interac-
tions with M. tuberculosis topoisomerase I in their
mechanism of action. Toxic compounds that reduce cell
viability by interaction with cell membranes or DNA
can be eliminated quickly in the pursuit of useful drug
leads. To facilitate the screening, permeability of E. coli
AS17 to small molecules can be enhanced by incorpora-
tion of mutations that affect the drug transporters [33]
or membrane structure [34].
Conclusions
Rapid genetic assays in E. coli have been described here
for assessing the relaxation activity and accumulation of
covalent cleavage complex of recombinant MtTOP1.
The genetic assay was used to identify positions in
MtTOP1 that can be converted to cysteine residues
0     400     100     25       6         2      400     100     25       6          2     ng enzyme
MtTOP1-K524C      CPM-MtTOP1-K524C
Figure 6 Relaxation activity of CPM labeled MtTOP1-K524C mutant. Serial dilutions of unlabeled MtTOP1-K524C mutant and CPM labeled
MtTOP1-K524C mutant proteins were assayed for relaxation of supercoiled plasmid DNA.
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CPM- MtTOP1-K524C + 100nM oligo
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Figure 7 FRET between CPM-MtTOP1-K524C and fluorescein labeled oligonucleotides. Increase in fluorescein fluorescence (520 nm) was
observed when CPM-MtTOP1-K524C was titrated with increasing concentrations of oligo internally labeled with fluorescein indicating the
occurrence of FRET (A). Little or no increase in fluorescein fluorescence was observed when titrations were carried out with oligo labeled at the
3’ end (B) or the 5’ end (C).
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as FRET-dye labeling sites to monitor interaction with
DNA substrate.
Methods
MtTOP1 clones
PCR reaction with PfuUltra II Fusion HS DNA polymerase
(from Stratagene) and genomic DNA of M. tuberculosis
strain H37Rv as template was used to generate the coding
sequence of MtTOP1 (gene Rv3646c). The PCR product
was cloned into plasmid pBAD/thio using the TOPO clon-
ing kit from Invitrogen to generate plasmid pBAD/thioM-
TOP. The 5’-PCR primer (5’AACCATGGCTGACCCG
AAAACGAAGGGCCG-3’) contained a recognition site
for the restriction enzyme Nco I, which was used to
remove the sequence coding for thioredoxin fusion tag
from plasmid pBAD/thioMTOP. Following ligation and
transformation of the restriction product, plasmid pMTOP
which has MtTOP1 expressed under the control of the
BAD promoter was obtained. Plamid pLIC-MTOP with
expression of MtTOP1 under the control of the T7 pro-
moter has been described previously [17]. Site directed
mutagenesis to introduce single amino acid substitutions
were carried out with QuikChange procedures using the
PfuUltra II Fusion HS DNA polymerase. Topoisomerase
gene coding regions in all isolated plasmid clones were
checked by DNA sequencing to confirm that no other
mutations were present.
Complementation of topA function in E. coli AS17 by
recombinant topoisomerase plasmid clones
E. coli AS17 (F
- topA17(am)p L L 1 ( Tet supD43,74)) [13]
transformants were grown overnight at 30°C, in Luria
Bertani (LB) broth containing tetracycline (15 μg/ml) and
antibiotics for selection of plasmid clones. Overnight cul-
tures were serially diluted in sterile phosphate buffered
saline and each dilution was plated on four LB agar plates
with antibiotics for selection of plasmid. Two of the
plates were incubated at 30°C, while the other two plates
were incubated at 42°C. The viable colonies were counted
after 48 hours of incubation at the respective tempera-
tures to determine colony counts in cfu/ml. The entire
study was repeated three times minimum for each plas-
mid clone. Complementation ratios were calculated by
dividing the cfu/ml at 42°C by the cfu/ml at 30°C for
each individual plasmid clone.
SOS induction and cell killing assays
Plasmid pMTOP expressing wild-type or mutant
MtTOP1-G116 S proteins under the control of the BAD
promoter were transformed into E. coli JD5 [JM103
dinDl ::MudI1734(KmR lacZ)] with b-galactosidase gene
under the control of the SOS regulon [6]. Transformants
isolated from LB plates with 100 μg/ml ampicillin and 2%
g l u c o s ew e r er e p l i c a t e do n t oL Bp l a t e sw i t h3 5μg/ml
X-gal, 100 μg/ml ampicillin and 0.002% arabinose. SOS
induction was indicated by the appearance of blue colo-
nies after overnight incubation at 37°C as previously
described for the isolation of SOS-inducing mutants of
Y. pestis topoisomerase I [6]. To measure the effect of
mutant MtTOP1 expression on viability, early exponen-
tial phase culture (OD600 =0 . 4 )o fE. coli JD5 transfor-
mants in LB medium with ampicillin (100 μg/ml) was
induced with 0.2% arabinose for 2 h before serial dilution
and plating on LB plates with 2% glucose and ampicillin,
followed by overnight incubation at 37°C. The number of
colonies (cfu/ml) obtained from the induced culture was
divided by the number of colonies from the control non-
induced culture to obtain the survival ratio.
Topoisomerase activity assay
MtTOP1-G116 S mutant enzyme expressed by induc-
tion of the BAD promoter with 0.2% arabinose in E. coli
strain GP200, a topA deletion mutant [35] was purified
as described previously [36]. Recombinant MtTOP1 pro-
teins with single-cysteine substitutions were expressed
via induction of the T7 promoter in E. coli ArcticEx-
press(DE3) RP strain (from Stratagene) and purified to
homogeneity with the same procedures used for wild-
type MtTOP1 [17]. The relaxation activity assay was
carried out with negatively supercoiled plasmid DNA
substrate as described [17]. The cleavage of supercoiled
plasmid DNA by MtTOP1 was assayed according to
published procedures [6].
CPM (7-diethylamino-3-(4’-maleimidylphenyl)-4-
methylcoumarin) labeling of MtTOP1-K524C protein
In preparation of the labeling reaction, a 32 μM solution
of MtTOP1-K524C in storage buffer (100 mM potassium
phosphate pH 7.4, 0.2 mM EDTA, 50% glycerol) was dia-
lyzed against labeling buffer (100 mM potassium phos-
phate, pH 7.4, 50 mM KCl, 10% glycerol) overnight at
4°C. After dialysis, the protein concentration was deter-
mined to be 16 μM. The protein solution was incubated
with 100 fold excess of TCEP (tris(2-carboxyethyl)phos-
phine) at room temperature for 10 min to keep the
cysteine residue in the reduced state. Labeling was carried
o u tb ya d d i t i o no f2 0f o l de x c e s so fC P M( M o l e c u l a r
Probes). Before and after each addition, the tube was
flushed with 95% nitrogen gas. After CPM addition, the
labeling reaction was allowed to proceed on ice for
6 hours. Removal of free dye was achieved by dialysis
against labeling buffer. The labeled protein was analyzed
by SDS-polyacrylamide gel electrophoresis and visualized
by fluorescence from the incorporated CPM with the
Storm 860 PhosphorImager and subsequently staining
with MicrowaveBlue (from Protiga).
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FRET experiments were performed in SCAN using the Var-
ian Cary Eclipse fluorescence spectrophotometer. Excitation
wavelength was set at 394 nm and emission was measured
between 400-600 nm. The excitation and emission slits
were set at 5 and 10 nm respectively. All FRET experiments
were performed in labeling buffer with 1 mM MgCl2 at
room temperature. CPM labeled MtTOP1-K524C (750
nM) was titrated with 50 and 100 nM solutions of oligonu-
cleotide substrate (5’-GCTGCAATGTGATTTGGGA-
TAATTAAGAGAGCAGC-3’) modified with fluorescein at
the 5’ or 3’ end (supplied by Sigma Genosys), or fluorescein
attached via a 6 carbon linker to position 5 of the thymine
base at the 20
th nucleotide (custom synthesized by Inte-
grated DNA Technologies). Control readings for the donor
spectrum were performed by titrating MtTOP1-CPM
K524C with buffer. Control readings for the acceptor spec-
trum were performed at excitation wavelength 495 nm by
titrating MtTOP1-CPM K524C with 50 and 100 nM of
fluorescein labeled oligos.
FRET efficiency calculations
FRET efficiency calculations were performed as
described [37]. The control readings for the donor spec-
trum were subtracted from the FRET readings and the
values obtained were divided by the control readings for
the acceptor spectrum to give (ratio) A using the follow-
ing equation:
()( ) / ratio F a F F AD A
D
D
D
DA
D =− ⋅
 
Since (ratio)A is linearly dependent on the energy
transfer efficiency (E), E was calculated using the follow-
ing equation,
Er a t i o d AA
D
A
A
D
D
A
A =− ⋅
+ { ( ) (/) } / { (/) }  
 
where d
+ = fraction of donor labeled molecules.
Additional material
Additional file 1: Quantitation of DNA nicking by MtTOP1-G116 S.
The percent of nicked DNA in each lane of Figure 2A was quantitated by
densitometry analysis. The increase in percent nicked DNA relative to the
control lane with no enzyme present is shown here.
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